KIT and acute myeloid leukemia: A recent retrospective study has shown that the progression-free survival (PFS) following allo-HSCT for SM-AML is merely 0.7 years (25).The absence of a KIT D816V mutation, the presence of a complex karyotype, and the lack of pre-transplant TKI usage adversely affected PFS post allo-HSCT.